AI assistant
ABBOTT LABORATORIES — Director's Dealing 2017
Feb 23, 2017
29777_dirs_2017-02-22_865db580-88f9-4f01-a8fa-ee3423bd1ef2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2017-02-17
Reporting Person: Blaser Brian J (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-02-17 | Common shares without par value | A | 26351 | — | Acquired | 171413 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-02-17 | Option (right to buy) | $44.40 | A | 182242 | Acquired | 2027-02-16 | Common shares (182242) | Direct |
Footnotes
F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 60,748 on 2/17/2018, 60,747 on 2/17/2019, and 60,747 on 2/17/2020.